Credit Suisse’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Credit Suisse’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-110,430	Closed	-$2.2M	–	4243
2022 Q3	$2.2M	Buy	110,430 +97,581	+759%	+$1.29M	﹤0.01%	1797
2022 Q2	$89K	Buy	12,849 +140	+1%	+$983	﹤0.01%	3559
2022 Q1	$118K	Sell	12,709 -1,490	-10%	-$15.9K	﹤0.01%	3462
2021 Q4	$201K	Buy	14,199 +4,257	+43%	+$73.7K	﹤0.01%	4274
2021 Q3	$230K	Buy	+9,942	New	+$235K	﹤0.01%	4185
2021 Q2	–	Sell	-12,079	Closed	-$325K	–	4236
2021 Q1	$339K	Sell	12,079 -19,593	-62%	-$707K	﹤0.01%	3958
2020 Q4	$1.1M	Buy	+31,672	New	+$1.38M	﹤0.01%	3272

Credit Suisse's FMTX Position: Q4 2022 in Review

Credit Suisse sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 110,430 shares — an estimated $2.2M sold.

Credit Suisse first reported a position in FMTX in Q4 2020 and held it in 7 quarters. The position peaked at $2.2M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Credit Suisse reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Credit Suisse sold 110,430 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $2.2M.
Credit Suisse first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Credit Suisse's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $2.2M in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.